Switch theme
Sign up to access all valuation multiples
Alteogen Inc Inc is engaged in the development and manufacture of next-generation biopharmaceuticals using NexP Fusion Technology. It also develops & markets biobetters and biosimilars by partnerships with pharmaceutical companies. It focuses on the areas such as biobetters, a proprietary antibody-drug conjugate, and antibody biosimilars with complexity.
2008
n/a
LTM Revenue $85.4M
LTM EBITDA $40.5M
$13.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alteogen has a last 12-month revenue of $85.4M and a last 12-month EBITDA of $40.5M.
In the most recent fiscal year, Alteogen achieved revenue of $70.1M and an EBITDA of $27.3M.
Alteogen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alteogen valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $65.8M | $70.1M | XXX | XXX | XXX |
| Gross Profit | $3.1M | $21.3M | XXX | XXX | XXX |
| Gross Margin | 5% | 30% | XXX | XXX | XXX |
| EBITDA | $0.3M | $27.3M | XXX | XXX | XXX |
| EBITDA Margin | 0% | 39% | XXX | XXX | XXX |
| Net Profit | -$5.6M | -$2.3M | XXX | XXX | XXX |
| Net Margin | -8% | -3% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Alteogen's stock price is KRW 387000 (or $264).
Alteogen has current market cap of KRW 20.63T (or $14.1B), and EV of KRW 20.45T (or $13.9B).
See Alteogen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13.9B | $14.1B | XXX | XXX | XXX | XXX | $0.91 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Alteogen has market cap of $14.1B and EV of $13.9B.
Alteogen's trades at 163.1x LTM EV/Revenue multiple, and 343.7x LTM EBITDA.
Analysts estimate Alteogen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Alteogen and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $13.9B | XXX | XXX | XXX |
| EV/Revenue | 198.8x | XXX | XXX | XXX |
| EV/EBITDA | 509.5x | XXX | XXX | XXX |
| P/E | 331.3x | XXX | XXX | XXX |
| P/E/Growth | 2.8x | XXX | XXX | XXX |
| EV/FCF | 715.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAlteogen's NTM/LTM revenue growth is 82%
Alteogen's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Alteogen's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Alteogen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Alteogen and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 39% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 9021% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 121% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 24% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 38% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alteogen acquired XXX companies to date.
Last acquisition by Alteogen was XXXXXXXX, XXXXX XXXXX XXXXXX . Alteogen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Alteogen founded? | Alteogen was founded in 2008. |
| Where is Alteogen headquartered? | Alteogen is headquartered in South Korea. |
| Who is the CEO of Alteogen? | Alteogen's CEO is Mr. Soon-jae Park. |
| Is Alteogen publicy listed? | Yes, Alteogen is a public company listed on KRX. |
| What is the stock symbol of Alteogen? | Alteogen trades under 196170 ticker. |
| When did Alteogen go public? | Alteogen went public in 2014. |
| Who are competitors of Alteogen? | Similar companies to Alteogen include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Alteogen? | Alteogen's current market cap is $14.1B |
| What is the current revenue of Alteogen? | Alteogen's last 12-month revenue is $85.4M. |
| What is the current EBITDA of Alteogen? | Alteogen's last 12-month EBITDA is $40.5M. |
| What is the current EV/Revenue multiple of Alteogen? | Current revenue multiple of Alteogen is 163.1x. |
| What is the current EV/EBITDA multiple of Alteogen? | Current EBITDA multiple of Alteogen is 343.7x. |
| What is the current revenue growth of Alteogen? | Alteogen revenue growth between 2023 and 2024 was 7%. |
| Is Alteogen profitable? | Yes, Alteogen is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
